OSBPL3 and breast cancer: Lefebvre et al. reported that OSBPL3 was more frequently mutated in metastatic breast cancer—and associated with poor outcomes—as compared to early breast cancer (Lefebvre et al., 2016), and Njeru et al. suggested the mutations of OSBPL3 contribute to carcinogenesis involving the deregulation of various molecular processes such as lipid metabolism, proliferation, and cell survival (Njeru et al., 2020).